Hood Leroy Md Phd Buys Shares of Omeros Corporation
Hood Leroy Md Phd acquired 15,000 shares of Omeros Corporation on June 18, 2026.
Key Points
- Hood Leroy Md Phd purchased 15,000 shares of Omeros Corporation on June 18, 2026, with no disclosed transaction value.
- Shares of Omeros Corporation traded at $10.28 on Monday, with a market cap of $744 million and a P/E ratio of 9.02.
- Analysts maintain a 'buy' rating on Omeros with price targets ranging from $9 to $45.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Hood Leroy Md Phd made a significant move by purchasing 15,000 shares of Omeros Corporation on June 18, 2026. This insider transaction did not have a disclosed value, but it reflects continued interest in the biotechnology company.
Insider Buying and Selling at Omeros Corporation
On June 18, 2026, several insiders, including Hood Leroy Md Phd, Diana Perkinson, Rajiv Shah, Thomas Bumol, Arnold Hanish, and Peter Demopulos, each bought 15,000 shares of Omeros Corporation. None of these transactions were planned under Rule 10b5-1 plans, indicating direct interest from the insiders.
Omeros Corporation Stock Down 44.5%
Shares of NasdaqGM:OMER traded near $10.28 on Monday. Omeros Corporation, with a market cap of approximately $744 million, has a P/E ratio of 9.02, reflecting its profitability. The stock has been volatile, with a 52-week low of $2.95 and a high of $17.65. It has a 50-day moving average of $12.22 and a 200-day moving average of $10.11, indicating recent downward pressure.
$OMER stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts continue to show confidence in Omeros Corporation. On April 21, 2026, D. Boral Capital maintained its 'buy' rating with a price target of $36. Similarly, HC Wainwright & Co. maintained a 'buy' rating with a target of $40 on January 8, 2026. The consensus remains positive, with a 'buy' recommendation and an average target price of $40.
About Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company based in Seattle, Washington. It focuses on discovering and developing small-molecule and protein therapeutics for immunologic diseases. The company is working on several products, including Narsoplimab for thrombotic microangiopathy and other conditions. Led by CEO Dr. Gregory A. Demopulos, Omeros employs about 175 people.
Bottom Line
Insider buying at Omeros Corporation, including Hood Leroy Md Phd's recent acquisition, suggests confidence in the company's future. Investors often track such moves for potential insights, although these transactions are disclosed after the fact. With analysts maintaining 'buy' ratings, Omeros remains a company to watch in the biotechnology sector.
Get Omeros Corporation alerts
New 13F filings, insider trades, and analyst moves on $OMER, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.